NCT05251844 is a NA clinical trial of receiving an email in Unauthorized Data Access, sponsored by Protenus, Inc..

Who is sponsoring NCT05251844?

NCT05251844 is sponsored by Protenus, Inc..

What drugs are being tested in NCT05251844?

Interventions in NCT05251844: receiving an email.

What condition does NCT05251844 study?

NCT05251844 studies Unauthorized Data Access.

Is NCT05251844 still recruiting?

NCT05251844 is currently completed. Last updated 23 February 2022.

Last reviewed 2022-02-23 · How we verify

NCT05251844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effectiveness of Email Alerting on Reducing Employees' Unauthorized Access to Protected Health Information

Completed NA Last updated 23 February 2022

What this trial tests

NA trial testing receiving an email in Unauthorized Data Access in 444 participants. Completed in 30 September 2021.

Timeline

1 January 2018

Primary endpoint
31 July 2018

30 September 2021

Quick facts

Lead sponsor	Protenus, Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	444
Start date	1 January 2018
Primary completion	31 July 2018
Estimated completion	30 September 2021
Sites	1 location across United States

Drugs / interventions tested

receiving an email

Conditions studied

Unauthorized Data Access — all drugs for Unauthorized Data Access →

Sponsor

Protenus, Inc.

Who can join

Eligibility, any sex, with Unauthorized Data Access. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the effectiveness of email warnings on reducing repeated unauthorized access to Protected Health Information (PHI), a randomized trial was conducted in a large academic medical center to understand the effectiveness of email warning on reducing repeated unauthorized access to PHI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effectiveness of Email Warning on Reducing Hospital Employees' Unauthorized Access to Protected Health Information: A Nonrandomized Controlled Trial.
Jiang JX, Culbertson N, Bai G. · · 2022 · cited 1× · PMID 35416994 · DOI 10.1001/jamanetworkopen.2022.7247

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05251844 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Protenus, Inc.
Last refreshed: 23 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05251844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing